Diabetes is characterized by high levels of glucose in the blood, resulting from insulin production defects and/or insulin action. An estimated 190 million people suffer from diabetes (2003 Diabetes Atlas: International Diabetes Federation); this extraordinary figure amounts to nearly 7% of the world's adult population and excludes those with IGT or gestational diabetes. In the United States alone, more than 18 million people are afflicted (National Diabetes Fact Sheet: American Diabetes Association) - an extraordinary and disproportionate share reflecting the growing prevalence of obesity, among other factors.

Diabetes can result in serious health complications including eye, kidney, and nerve disease, and can lead to premature death, but there are steps that people with diabetes can take to lower the risk of such complications. Research studies around the world have shown that improved glycemic control is a critical component of reducing complications associated with the disease.

In order to facilitate optimal treatment, therefore, diabetics require frequent measuring of blood glucose levels, with patients requiring numerous measurements on a daily basis.

However, the routine measurement of glucose levels remains invasive, involving most commonly the pricking of finger tips. The pain and inconvenience associated with finger sticks have resulted, not surprisingly, in a sub-optimal measurement regimen for many patients. A reliable, inexpensive, non-invasive device could greatly increase compliance and help many diabetics better manage their disease.

At this time, there are virtually no viable devices for the non-invasive measurement of glucose levels on the market.

Most attempts to develop such non-invasive devices have featured the use of infra red (IR) or near infra red (NIR) to obtain optical signatures which can indicate the level of blood glucose, but limitations inherent in this technology led to data analysis problems and caused such efforts to fall short.

Our product succeeds where others have failed.

GlucoTrack is based on three independent technologies which operate simultaneously - and non-invasively - to provide a reliable and accurate measurement.

  Back to top




In the year 2025, the prevalence of diabetes is expected to be more than doubled in Africa, the Eastern Mediterranean and Middle East and South-East Asia, and rise by 20% in Europe, 50% in North America, 85% in South and Central America and 75% in the Western Pacific. For developing countries, there will be a projected increase of a 170% of cases; for developed countries, there will be a projected rise of 42%. [Diabetes Atlas, second edition, IDF (International Diabetes Federation), 2003]

  Back to top